Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine

0365072 - ÚMG 2012 RIV GR eng J - Článek v odborném periodiku
Mikyšková, Romana - Indrová, Marie - Šímová, Jana - Bieblová, Jana - Bubeník, Jan - Reiniš, Milan
Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine.
Oncology Reports. Roč. 25, č. 6 (2011), s. 1683-1689. ISSN 1021-335X. E-ISSN 1791-2431
Grant CEP: GA ČR GA301/09/1024; GA ČR GA301/07/1410
Grant ostatní: EK(XE) EU-FP6-NOE018933
Výzkumný záměr: CEZ:AV0Z50520514
Klíčová slova: gemcitabine * human papilloma virus * interleukin 12 * lung metastases * cellular vaccines * immunotherapy
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 1.835, rok: 2011

Genetically modified tumour cells producing cytokines such as IL-12 are potent activators of antitumour immune responses and a promising therapeutic modality when combined with chemotherapy. We examined whether IL-12-producing cellular vaccines can augment chemotherapy of HPV 16-associated murine tumours with cytostatic agent gemcitabine (GEM). Peritumoral administration of IL-12-producing tumour vaccines enhanced the effect of cytoreductive therapy with GEM in non-metastasizing murine carcinoma TC-1 and in metastasizing murine carcinoma MK16. Lung metastases in mice were substantially decreased. In surgical minimal residual tumour disease IL-12-producing tumour vaccine and GEM after MK16 tumour surgery also reduced tumour recurrences and metastases. Tumour inhibitory effects of GEM plus IL-12 were associated with high production of interferon-γ by splenocytes. IL-12-producing vaccine can thus enhance the effect of GEM chemotherapy in some HPV16-associated murine tumour models.
Trvalý link: http://hdl.handle.net/11104/0200408